HempFusion is taking part in and sponsoring a new study taking place about the impact of CBD on human health. The Denver, Colo.-based company will be one of 10 companies participating in ValidCare’s study, which will seek to determine what, if any, impact daily use of hemp-derived CBD or CBD isolate has on the human liver.

"We are excited that HempFusion is one of the select companies participating in this study as they have demonstrated leadership in regulatory compliance and concern for consumer safety," stated Patrick McCarthy, CEO of ValidCare. "What makes this study unique is we are capturing real world evidence from real consumers, specifically on how they use CBD products and how their bodies react to those products, particularly with respect to liver safety. We believe this real world evidence is important to the FDA and could be used to guide policy moving forward.”

ValidCare currently anticipates the study will begin in the third quarter of 2020, with the aim of completing it by the end of the year. The company noted that the third-party data generated by the study is intended to address some of the Food and Drug Administration’s specific requests about CBD products.

"We are incredibly proud to participate in ValidCare's study and help advance scientific research surrounding CBD,” said Jason Mitchell, co-CEO of HempFusion. "As a company, we are built on a foundation of regulatory compliance as well as consumer safety and participation in this study helps establish HempFusion as a leader in the global CBD industry.”